Evidence map›Paper›PMID 35587833›Full record

ReviewRheumatology international2022

Nanotechnology applications in rheumatology.

Arvind Nune, Bhupen Barman, Hem R Sapkota, Pranav Ish, Easwaradhas G Chelliah, Masroor Diwan, Apam Chiphang, Karthikeyan P Iyengar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Arvind NuneSouthport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, United Kingdom. arvind.nune@nhs.net.ORCID 0000-0002-3849-614X
Bhupen BarmanDepartment of Medicine, Northeastern Indira Gandhi Regional Institute of Health and Medical Sciences, NEIGRIHMS0, Shillong, Meghalaya, India.ORCID 0000-0002-5433-1310
Hem R SapkotaRoyal Wolverhampton Hospital NHS Trust, Wolverhampton, WV10 0QP, United Kingdom.ORCID 0000-0003-2314-2637
Pranav IshDepartment of Pulmonary and Critical Care Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, 110029, India.ORCID 0000-0003-1701-4970
Easwaradhas G ChelliahWrightington Hospital, Wigan, WN6 9EP, United Kingdom.
Masroor DiwanSouthport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, United Kingdom.
Apam ChiphangSouthport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, United Kingdom.
Karthikeyan P IyengarSouthport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, United Kingdom.ORCID 0000-0002-4379-1266
Southport and Ormskirk Hospital NHS Trust · GBNorth Eastern Indira Gandhi Regional Institute of Health and Medical Sciences · INVardhman Mahavir Medical College & Safdarjung Hospital · INWolverhampton Hospital · GBWrightington Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicine (NM) is the medical use of nanotechnology (NT). NT is the study and control of nanoscale structures (between approximately 1 and 100 nm). Nanomaterials are created by manipulating atoms and molecules at the nanoscale, resulting in novel physical and chemical properties. With its targeted tissue delivery capabilities, NT has enabled molecular modulation of the immune response and underlying inflammatory responses in individuals with rheumatic diseases (RD). NM has enabled targeted drug delivery, reduced adverse effects on non-target organs, raised drug concentration in synovial tissue, and slowed the progression of immune-mediated RD such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Thus, NM has evolved in rheumatology prevention, diagnosis, and therapy. Animal models have proven superior outcomes to conventional techniques of treating specific illnesses. Nanodiamond (ND) immunomodulatory applications have been proposed as an alternative to traditional nanoparticles in the diagnosis and treatment of RA due to their small size and ability to be removed from the body without causing harm to the patient's organs, such as the liver. However, human clinical NM needs more research. We conducted a literature review to assess the present role of NM in clinical rheumatology, describing its current and future applications in the diagnosis and treatment of rheumatic diseases.

Indexed as

Arthritis, RheumatoidLupus Erythematosus, SystemicNanodiamondsRheumatic DiseasesRheumatologyAnimalsHumansNanotechnologyNanodiamondsDrug deliveryNanomedicineNanotechnologyRheumatic diseasesRheumatologyTargeted delivery

Identifiers

PMID35587833
OpenAlexW4280521595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.